Cargando…
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial
BACKGROUND: Adjuvant therapies can prevent/delay bone metastasis development in breast cancer. We investigated whether serum bone turnover markers in early disease have clinical utility in identifying patients with a high risk of developing bone metastasis. METHODS: Markers of bone formation (N-term...
Autores principales: | Brown, Janet, Rathbone, Emma, Hinsley, Samantha, Gregory, Walter, Gossiel, Fatma, Marshall, Helen, Burkinshaw, Roger, Shulver, Helen, Thandar, Hasina, Bertelli, Gianfilippo, Maccon, Keane, Bowman, Angela, Hanby, Andrew, Bell, Richard, Cameron, David, Coleman, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093369/ https://www.ncbi.nlm.nih.gov/pubmed/29425304 http://dx.doi.org/10.1093/jnci/djx280 |
Ejemplares similares
-
Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study
por: Wilson, Caroline, et al.
Publicado: (2016) -
Optimising trial monitoring on the AZURE trial
por: Matthews, Geraldine A, et al.
Publicado: (2011) -
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
por: Coleman, R.E., et al.
Publicado: (2018) -
Bone Turnover Markers: Basic Biology to Clinical Applications
por: Schini, Marian, et al.
Publicado: (2022) -
Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover
por: Wilson, Caroline, et al.
Publicado: (2016)